Bellerophon Therapeutics Inc

NASDAQ:BLPH   3:09:51 PM EDT
1.02
+0.01 (+0.50%)
Regulatory, Earnings Announcements

Bellerophon Provides Clinical Program Update And Reports Third Quarter 2022 Financial Results

Published: 11/14/2022 13:47 GMT
Bellerophon Therapeutics Inc (BLPH) - Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results.
Bellerophon Therapeutics Inc - Phase 3 Rebuild Registrational Study Enrollment of Inopulse for Treatment of Fild is Approaching Completion.
Bellerophon Therapeutics Inc - Reduced Study Size is 140 Fild Patients Who Will Be Treated With Either Inopulse at a Dose of Ino45 Or a Placebo.
Bellerophon Therapeutics Inc - Received FDA Clearance to Conduct Phase 2 Study and Co is Currently Assessing Next Steps for Study.
Bellerophon Therapeutics Inc - Qtrly Loss per Share$0.53.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.48

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.